Purpose of the Merger. The purpose of the Merger is to combine the organizations and memberships of NEK and CVF and the services offered, and functions performed by each into a single, comprehensive and cost-efficient organization that is better able to serve the interests of the citizens of Vermont in their districts.
Purpose of the Merger. (See page 14) -- The purpose of the merger is to allow Saw Mill and the Management Shareholders to acquire Jasox. Xx the merger is completed, Jasox xxxmon stock will cease to be publicly traded and holders of common stock (other than Jasox itself, Merger Sub and shareholders who perfect their dissenter's rights described elsewhere in this Proxy Statement) will receive $11.25 in cash per share. INTEREST OF MANAGEMENT SHAREHOLDERS (See page 39) -- The Management Shareholders have interests in the merger that are different from your interests as a shareholder. Collectively, the Management Shareholders now beneficially own 7,687,812 shares of Jasox xxxmon stock representing approximately 37.6% of the outstanding common stock. In connection with the merger, the Management Shareholders will contribute a total of 2,437,262 shares of common stock valued at an aggregate average of $10.13 per share to Parent in exchange for shares of Parent. In exchange for their remaining 5,250,550 shares of Jasox xxxmon stock, the Management Shareholders will receive the cash consideration of $11.25 per share resulting in an aggregate average value of approximately $10.90 per share in cash and stock being received by the Management Shareholders for their shares of Jasox xxxmon stock in connection with the Merger. The Management Shareholders also will continue to serve in their positions as executive officers of Jasox xxxer the merger and will enter into new employment agreements with the surviving corporation. The Management Shareholders have agreed to allow Saw Mill to vote their shares in favor of the Merger.
Purpose of the Merger. The Alfresa Group’s 22-24 Mid-term Management Plan Leap into the Future “An Evolving Healthcare Consortium”, which was announced today, outlines two key objectives of the Group's management policy: "Enhancement of business model" and "creation of new value" Alfresa Pharma, with its strength in manufacturing, import/export, and marketing of diagnostic reagents, medical devices, and materials for pharmaceuticals in addition to manufacturing and marketing of pharmaceuticals, and Sannova, with its expertise in contract manufacturing of pharmaceuticals and quasi-drugs, will combine their respective managerial resources into a new company that will lead the Alfresa Group's manufacturing business segment. The new company to be formed through the Merger will strive to deliver customer satisfaction by creating new value, and will contribute to the realization of the Alfresa Group’s Vision “to become a Healthcare Consortium® that provides products and services in every health-related field.”
Purpose of the Merger. (a) It is the express purpose of this Merger, that AXIS CA become a publicly traded vehicle through its merger with AXIS DELAWARE.
